Eli Lilly and Co (LLY)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 29% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+51% over the past year+6
- 52-week positionAbove the midpoint of its 52-week range+9
- QualityRevenue growing 50% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 Dominant catalyst: product, driven by the UK launch and NHS pricing assessment for Foundayo. Continuation likelihood is moderate, as regulatory and market-access details remain unresolved. Informational only — not financial advice.
- Eli Lilly (NYSE:LLY): A Dividend Quality Pick with Sustainable GrowthChartMill · 2026-08-24
- Novo Nordisk: Don't Ignore This Dirt-Cheap Buying OpportunitySeekingAlpha · 2026-08-24
- Sanofi: Trump's Vaccine Policy Won't Break The StorySeekingAlpha · 2026-08-24
- Eli Lilly Makes Foundayo Available To Eligible UK Adults Privately, Seeks NICE Assessment For NHS Use At £100-£120 PricingBenzinga · 2026-08-24
- Prediction: Eli Lilly Could Be One of the Biggest Winners of the Next Decade. Here’s Why.Yahoo · 2026-08-23
Any AI summary is an interpretation of public news, not advice or a price target.